Funding will advance QuantHealth’s R&D, product innovation, and commercial expansion following 8x sales growth in 2025
TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, a global leader in AI-driven clinical trial simulation, today announced a $45 million Series B. The round was led by Qumra Capital, with support from additional investors, including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures.
Building on strong momentum and growing adoption of its solutions, QuantHealth will use the new capital to scale its enterprise-wide impact and accelerate adoption of simulation-first clinical development. With this approach, life sciences organizations move away from designing clinical trials based on historical benchmarks and subjective assumptions, and toward launching trials that have been tested, optimized, and de-risked through AI-driven simulation before a patient is enrolled or capital is deployed.
Key investments include:
- Advancing its R&D capabilities with next-generation AI models, deeper scientific validation, expanded data sets, and increased therapeutic coverage
- Growing its workforce to support increasing industry demand and deliver expert-driven client engagements
- Expanding its product portfolio across the clinical and commercial lifecycle, from trial design through go-to-market positioning, with a focus on demonstrating measurable impact
Clinical trials remain one of the most costly and uncertain phases of drug development, with more than 90% of drugs that enter clinical development ultimately failing, approximately 75% due to efficacy and safety. As pressure mounts to bring therapies to market faster, while still ensuring safety and efficacy, pharmaceutical and biotech companies are increasingly turning to predictive technologies to guide decision-making.
“Today, clinical development decisions are still largely made through real-world iteration—running trials, waiting for results, and adjusting at significant cost and risk. We’re fundamentally changing that model,” said Orr Inbar, CEO and co-founder of QuantHealth. “With our predictive simulations, teams can evaluate clinical and commercial decisions before enrolling a single patient or committing capital. This funding allows us to scale that approach, making simulation a standard step in development and fundamentally improving how drugs are brought to market.”
To date, QuantHealth has simulated more than 600 clinical trials across 30 indications, achieving up to 90% predictive accuracy. The company plans to expand to more than 40 indications across its core therapeutic focus areas, including oncology, cardiometabolic, and inflammation.
“AI has already transformed drug discovery, and clinical trials are the next frontier. It’s a market in which hundreds of billions of dollars are spent annually on clinical trials, and one that is ripe for a smarter, more efficient approach,” said Reut Yehuda Golan, partner at Qumra Capital. “QuantHealth is at a significant inflection point: their technology is mature, the market is ready for change, and the proof points are already there. At Qumra, we invest in companies that transform industries, and QuantHealth is exactly that, a company on its way to defining and leading a massive category, with groundbreaking technology that is already widely adopted across the world’s leading pharmaceutical companies.”
“As one of QuantHealth’s earliest investors, we have had the opportunity to watch the company help define an emerging category at the intersection of AI and clinical development,” said Cris De Luca, Partner at Sanofi Ventures. “As the pharmaceutical industry increasingly looks to leverage AI to improve decision-making across the development lifecycle, simulation technologies are becoming an important part of the drug development toolkit. QuantHealth has been an early pioneer in this space, and we look forward to the company’s continued growth and impact across the industry.”
To learn more about AI in clinical development or QuantHealth, please visit quanthealth.ai.
About QuantHealth
QuantHealth is the global leader in AI-powered clinical trial simulation. The company combines the industry’s most advanced clinical trial simulations portfolio, spanning more than 600 trials and 30 indications, with one of the largest real-world datasets in the category. Its solutions enable pharmaceutical and biotechnology organizations to optimize trial design, reduce risk, and accelerate development timelines. QuantHealth partners with 12 of the world’s top 20 pharmaceutical companies to improve clinical success rates and bring better therapies to patients faster.
Contacts
Media Contact
Mia Hinz
917-574-3319
quanthealth@solcomms.co
